REG - Belluscura PLC - Directorate Change

BelluscuraAnnouncement

11/07/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240711:nRSK0625Wa&default-theme=true

RNS Number : 0625W  Belluscura PLC  11 July 2024

11 July 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company")

 

Directorate Change

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces that Jonathan
Satchell, Non-executive Director, has informed the Board that he intends to
step down from his role as a Non-executive Director with effect from 11 July
2024.

Jonathan was appointed to the Board in February 2024 following the acquisition
of TMT Acquisition plc by the Company.

Adam Reynolds, Chairman of Belluscura, commented:

"On behalf of the Board, I would like to thank Jonathan for his valued
contribution during his time on the Board of Belluscura. His insights and
advice have been greatly appreciated since he joined the Board following the
Company's acquisition of TMT Acquisition plc and we wish him well with his
other roles."

-Ends-

 

For further information please contact:

 

 Belluscura plc                          Tel: +44 (0)20 3128 8100
 Adam Reynolds, Chairman

 SPARK Advisory Partners Limited         Tel: +44 (0)20 3368 3550

 Nominated Adviser
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited                 Tel: +44 (0)20 3903 7715

 Broker
 Russell Cook / Nicholas Chambers

 MHP                                     Tel: +44 (0)20 3128 8100

 Financial PR & Investor Relations       email: Belluscura@mhpgroup.com
                                         (file:///C:/Users/Neil%20Baldwin/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/HN4QW5O2/diamond@mhpgroup.com)
 Katie Hunt/Matthew Taylor

 

About Belluscura plc (https://belluscura.com/)

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQKDBDKBKDBOD